Est. 2026  ·  New England

We back the bold. Seed-stage capital investing at the inflection point of the intelligence era.

Get in Touch
Our Investment Thesis
We co-pilot from term sheet to exit.
01 / EXECUTION
From idea to traction — fast.
We've built companies from fundamentals. We know which decisions compound and which detours cost years. Our founders get operational co-piloting, not passive capital.
02 / VALUATION
Lean teams command asymmetric returns.
Today's top companies are built with smaller teams and less capital than ever before. We see the valuation opportunity before the market does — and we act with precision.
03 / IMPACT
The markets that can't wait.
Life sciences and data analytics are not patient industries. The buyers who must adopt or be left behind create the exits. We invest where that urgency lives.
The Founding Edge

Built from
fundamentals.

20+
Years cross-industry
3×
Founder, operator, investor
Seed
Stage only — precision over breadth

Dr. Gopal Chopra's path from neurosurgery to venture capital isn't a career pivot — it's a coherent evolution. Surgery is an exercise in calibrated intervention. The same discipline applies when evaluating a founding team.

With an MBA from Duke Fuqua and two decades across clinical practice, M&A investment banking, and advisory roles, Gopal evaluates technology not just by what it does today, but by the hurdles it can surmount and the markets it can command.

Validare's founders aren't looking for capital. They're looking for the colleague who has held the scalpel, sat in the boardroom, and knows exactly which decision they should make right now.

Investment Focus

Where we
deploy capital.

Health Tech

Digital health platforms, clinical decision support, remote monitoring, and care-delivery infrastructure. Technology that improves outcomes and scales access without adding cost.

Seed Stage

Life Sciences

Proteomics, biotech, health data platforms, and healthcare-adjacent AI. Companies at the intersection of biology and technology where the science is ready and the market is urgent.

Seed Stage

Data Analytics

AI-enabled workflows, intelligent infrastructure, and data platforms that create defensible moats. Companies where data is the durable competitive advantage.

Seed Stage

Education

AI-native learning platforms, vocational credentialing, and workforce development tools. Companies democratizing access to skills that matter in the intelligence inflection.

Seed Stage

Autonomous Robotics

Intelligent systems, human-machine collaboration, and physical AI that can be built lean and deployed fast. Companies where software-defined hardware creates asymmetric defensibility.

Seed Stage

Artificial Intelligence

Foundation model applications, agentic systems, and AI-native products across every vertical we back. The enabling layer that compounds every other investment we make.

Seed Stage
How We Work

The intervention
methodology.

01
Identify
Companies that can be built quickly and efficiently with lean teams. Technologies that address critical market needs where buyers cannot afford to wait.
02
Evaluate
Technology capability, market applicability, and hurdle surmountability. We assess the insight of the technology — not just the mechanism, but the real-world path to adoption.
03
Co-Invest
Capital plus operational co-piloting. We've been the CEO, the advisor, the M&A intermediary. Our founders get a colleague who has made every one of their decisions before.
04
Accelerate
Strategic insight for board communications, fundraising structure, pivots, and pilots. Where should we do our POV? How do we structure the next round? We know these answers.
05
Exit
High-value exits to strategics who see the threat. Large incumbents in life sciences and data analytics cannot be left behind — and their urgency creates the premium we seek.
Portfolio

Early traction.
Already compounding.

One Intelligence ↗

Post-quantum trust infrastructure for AI systems. $10M SAFE raise at $150M pre-money. Live go-to-market with enterprise pilots underway.

Cybersecurity AI

Mesh Health Solutions ↗

AI-first prior authorization and clinical risk platform. Live in production, generating revenue within weeks of go-live. $3M pre-money convertible note.

HealthTech · Clinical AI

Adapt Global Studios ↗

Global linguist marketplace for localized video — 4× faster, 4× cheaper. $5B current TAM, enterprise customers live. $5M pre-money SAFE.

LinguisticTech · Media AI

TREVI ↗

AI for structured topic research and curriculum management — exploratory learning with referenceable frameworks. $11M pre-money SAFE.

EdTech

Additional positions held privately. Details available on request.

Leadership & Partners

Guided by insight.
Built by operators.

"I recognize disruptive fundamentals and how that can transform markets. I believe it will be the domain experts that define and create the new intelligence first economy."
— Dr. Gopal K. Chopra, Founding General Partner
Founding Leadership
Wil Bolivar
Wil Bolivar
Advisory Partner — Technology & AI
Partner & CTO at SoftBank Investment Advisers. Led AI strategy and cybersecurity across a global portfolio. Board observer at Arkose Labs. Advised Zoom and LinkedIn ahead of IPO.
Dr. Gopal K. Chopra
Dr. Gopal K. Chopra
Founding General Partner
Neurosurgeon, prior Stanford & Duke faculty, and former Lazard banker who advised on more than $30B in M&A, IPOs, and private financings. Built three med/health-tech companies to major exits. Creator of patents spanning surgical navigation, vascular devices, and clinical AI.
Tera Kull
Tera Kull
Principal
Senior Director of People Strategy & Culture at LabCentral. Brings operational discipline, LP relationship management, and founder network development to Validare's portfolio.
Venture Partners & Leadership
Matt Greenfield
Matt Greenfield
Venture Partner
Rethink Education Capital
James Bergin
James Bergin
Venture Partner
Johnson & Johnson
Geoffrey Smith
Geoffrey Smith
Advisory Partner
Digitalis Ventures
Advisory Network — Domain Strength
Harsh Maheshwari
Harsh Maheshwari
AI & Enterprise Software
Super{Set}
Rick Smith
Rick Smith
Health Services
Byram & BioScrip
Riju Khetarpal
Riju Khetarpal
AI & Digital Health
Google Health
Founders & Co-Investors Welcome

Back the bold.

Applications from founders and co-investors welcome. We respond to every message personally.

Your message is sent securely to Validare's team. We respond personally.